Becton, Dickinson and Company $BDX Shares Acquired by Chicago Capital LLC

Chicago Capital LLC raised its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 23.7% in the second quarter, HoldingsChannel reports. The firm owned 1,227 shares of the medical instruments supplier’s stock after acquiring an additional 235 shares during the period. Chicago Capital LLC’s holdings in Becton, Dickinson and Company were worth $211,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Saudi Central Bank acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at about $26,000. Smallwood Wealth Investment Management LLC acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at about $27,000. Alpine Bank Wealth Management acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at about $29,000. Cornerstone Planning Group LLC boosted its stake in Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at about $31,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,023 shares of company stock worth $562,036 in the last 90 days. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Up 2.0%

BDX stock opened at $190.90 on Thursday. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The firm has a market cap of $54.72 billion, a PE ratio of 34.33, a P/E/G ratio of 1.51 and a beta of 0.25. The firm has a 50 day simple moving average of $188.71 and a 200 day simple moving average of $188.20. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same period in the prior year, the business earned $3.50 earnings per share. The business’s quarterly revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were paid a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is currently 74.82%.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of research analyst reports. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Royal Bank Of Canada initiated coverage on shares of Becton, Dickinson and Company in a research note on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 price target for the company. Finally, Argus upped their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Three research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.